Further investigation revealed FOXA1 and TYMS mRNA expression were significantly associated with the clinical stage of CRC (P < .05 for stage III/IV vs. stage I/II; Supplemental Figure S1A‐F). This evidence concerns the gene FOXA1 and colorectal carcinoma.